Beijing, China

Qipeng Yuan

This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Beijing University of Chemical Tehcnology. Active years: 2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qipeng Yuan. Retrieved from https://idiyas.com/inventor/qipeng-yuan-kdh2uls0

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Qipeng Yuan: Innovator in Cancer Treatment

Introduction

Qipeng Yuan is a notable inventor based in Beijing, China. He has made significant contributions to the field of cancer treatment through his innovative research and development.

Latest Patents

Qipeng Yuan holds a patent for a method of treating or preventing tumors using 1-(alkylsulfinyl)-2-isothiocyanatoalkyl-1-alkene. This method involves administering a pharmaceutical composition, health product, or food additive containing this compound to patients or animals in need of treatment for cancer and tumors.

Career Highlights

He is affiliated with the Beijing University of Chemical Technology, where he continues to advance his research in the field of oncology. His work has garnered attention for its potential impact on cancer therapies.

Collaborations

Some of his notable coworkers include Ming Yang and Hao Liang, who contribute to the collaborative efforts in his research endeavors.

Conclusion

Qipeng Yuan's innovative approach to cancer treatment exemplifies the importance of research and development in the medical field. His contributions are paving the way for new therapeutic options for patients.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…